INTRODUCTION {#s0010}
============

Approximately 10% of dairy calves die, and calf morbidity is a significant issue ([@bb0075]). Although the primary reason for morbidity and mortality in the preweaned dairy calf is typically enteric, bovine respiratory disease (**BRD**) is of significant concern in calves over 1 mo of age ([@bb0065]) and is the primary cause of mortality after weaning, averaging 1.8% ([@bb0075]).

With BRD being a primary cause of calf death, metaphylactic antibiotic treatments of weaned beef and dairy calves are implemented on many farms ([@bb0070]). Draxxin (100 mg/mL tulathromycin; Zoetis, Florham Park, NJ) is approved for control of BRD in beef cattle, nonlactating dairy cattle (including dairy calves), and veal calves at high risk of developing BRD associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*, and *Mycoplasma bovis*. Although government agencies encourage less use of antibiotics in livestock ([@bb0090]), the metaphylactic use of tulathromycin in commingled dairy calves has been reported to lower the incidence of diarrhea, otitis media, and BRD and improve growth ([@bb0050], [@bb0055], [@bb0060]) and suggested to possibly reduce antibiotic resistance ([@bb0085]). In calves over 2 mo of age and metaphylactically treated with TUL at approximately 3 d of age, TUL increased ADG and reduced the incidence of diarrhea and otitis media ([@bb0060]). In calves metaphylactically treated with TUL versus oxytetracycline at approximately 2 mo of age, ADG and withers height change were increased to approximately 3.2 mo of age in calves that had not been treated for disease, and the incidence of respiratory infection was reduced ([@bb0050], [@bb0055]). Other peer-reviewed research with TUL in young dairy calves was not found.

Use of TUL to reduce risk of morbidity and mortality in dairy calves has been observed by [@bb0050], [@bb0055], [@bb0060]); therefore, our objective was to test the metaphylactic use of TUL in preweaned dairy calves and evaluate the carryover effects after weaning. We implemented this study during a period of approximately 4 mo of treating approximately 20% of our calves for BRD, an untypically high rate for our research unit.

MATERIALS AND METHODS {#s0015}
=====================

Calves were cared for by acceptable practices as described in the *Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching* ([@bb0020]). In phase 1, 2 groups of 48 male Holstein calves (96 total) initially 2 to 4 d of age from a single dairy farm were transported 3.5 h to the Nurture Research Center in southwest Ohio. The second group arrived 35 d after the first group. Upon arrival, calves were randomly assigned to receive a s.c. injection of Draxxin (2.5 mg of tulathromycin/kg of BW; **TUL**) at arrival (d −1) and again at weaning (d 42) or receive no injections (**CON**). Calves were housed in 1.2 m × 2.4 m individual pens with a coarse-rock, tile-drained floor bedded with straw in a curtain-sided, naturally ventilated barn with no added heat for 56 d. Milk replacer (**MR**) was fed at 0.66 kg of DM daily for 39 d and then 0.33 kg of DM daily for 3 d. The MR was manufactured with whey, whey protein concentrate, and animal fat (25% CP, 18% fat; [Table 1](#t0010){ref-type="table"} ), reconstituted to 14% solids with warm water, and fed at 0630 and 1400 h daily. A high-grain, textured starter ([Table 1](#t0010){ref-type="table"}; fed at approximately 1300 h) and water (fed at approximately 0800 h) were fed free choice for the 56 d of phase 1. Every other bag of MR and starter was sampled and composited for nutrient analysis. Management practices including vaccinations and medical treatments during the trial were based on the recommendations of the herd veterinarian.Table 1Analyzed nutrient composition of feedsTable 1FeedMilk replacer[1](#tf0010){ref-type="table-fn"}Starter[2](#tf0015){ref-type="table-fn"}Grass hayDM, % as fed93.487.787.6DM basis, % CP25.820.313.9 Fat18.33.72.8 ADF---7.937.4 NDF---14.661.6 Sugar---7.72.1 Starch---39.61.8 Ash6.66.99.3 Calcium0.660.930.41 Phosphorus0.630.630.36 Magnesium0.090.290.16 Potassium1.440.992.83[^1][^2]

The day after arrival at approximately noon approximately 5.5 h after feeding MR, the calves were weighed (d 0, initial BW). At this time, blood was sampled intravenously, serum was separated by centrifugation at 3,000 × *g* (VWR, Batavia, IL) at 20°C for 15 min, and serum protein concentration was estimated using an optical refractometer (ATAGO USA Inc., Bellevue, WA). Calves were weighed initially and weekly thereafter at approximately noon. Body condition score (1 being thin and 5 being obese, modified from [@bb0095]) and hip widths using a caliper were measured initially and every 2 wk thereafter. Phase 1 was conducted in consecutive months of October 2014 to January 2015. The average temperature in the nursery was 6°C with a range from −8 to 27°C. The average relative humidity was 74% with a range from 13 to 100%.

Feces were scored daily using a 1-to-5 scale with 1 being normal and 5 being watery (modified from [@bb0040]). Calves with fecal scores of 3 or greater (considered abnormal fecal scores) received oral electrolytes that were not counted as medical treatments. During the first 28 d, the first abnormal feces (fecal score of 3 or greater) per calf was sampled and mixed. An aliquot was tested for *Cryptosporidium*, *Rotavirus*, *Coronavirus*, or K99 *Escherichia coli* using lateral immunochromatography strips (Biox Diagnostics, Jemelle, Belgium). Antibiotic medical treatments were recorded daily. Bovine respiratory disease was defined as one or more of the following symptoms: coughing, nasal discharges, labored breathing, and rectal temperatures \>39.4°C. Baytril 100 (Bayer Healthcare, Shawnee Mission, KS; 5 mL s.c.) was administered to calves with BRD. Banamine (Merck, Madison, NJ; 1.5 mL i.v.) was administered for lethargy. Navel infections were treated with 5 mL of penicillin G procaine i.m. (300,000 units/mL; Agri Laboratories LTD, St. Joseph, MO) daily for 7 d. On d 28, 42, and 56, an experienced technician auscultated lungs of calves (right, anterior side of calves) to assist in identification of respiratory disease.

Calves received an intranasal respiratory disease vaccine (TSV-2, Zoetis, Parsippany, NJ) and s.c. injections of vitamins A, D, E (Vital E − A + D, Merck Animal Health) and Se (MU-SE, Merck Animal Health) upon arrival. Calves received an injection of Bovashield Gold 5 (Zoetis) at d 7 and again at d 28. Calves were surgically castrated and dehorned at 36 d of age.

In phase 2, the same calves from phase 1 were grouped by CON and TUL and moved to group pens (12 pens per treatment with 4 calves per pen) for the next 56 d. The pens had 6.5 m^2^ of outside pen space and 1.35 m^2^ of inside pen space per calf. Inside pen space was bedded with straw, and there was no added heat. The same starter fed in phase 1 was blended with 5% chopped grass hay ([Table 1](#t0010){ref-type="table"}). Starter-forage mix and water were fed free choice. Every other bag of starter and every bale of hay was sampled and composited for nutrient analysis. Initially and at 84 and 112 d, calves were weighed and scored for body condition and hip widths were measured. The trial was conducted in consecutive months of December to March immediately following phase 1 for each group of calves. Average temperature in phase 2 was −2°C with a range from −22 to 15°C. Average relative humidity was 73% with a range from 38 to 100%.

Composites of feeds and refused feed were analyzed ([@bb0010]) for DM (oven method 930.15), ash (oven method 942.05), CP (Kjeldahl method 988.05), fat (alkaline treatment with Roese-Gottlieb method 932.06 for MR; diethyl ether extraction method 2003.05 for starters and hay), NDF with ash by the procedure of [@bb0080] without sodium sulfite or α-amylase, ADF with ash ([@bb0045]), starch (α-amylase method; [@bb0025]), and sugar (colormetric method; [@bb0015]). Nutrient analysis of the refused feed for each wk and pen was similar to composition of feed offered.

In phase 1, data were first grouped by week, except hip width and BCS change, which were grouped by 14-d periods. The data were analyzed as a completely randomized block design with repeated measures when applicable by Proc Mixed in SAS (version 8, SAS Institute Inc., Cary, NC). The 48 calf groups received 35 d apart were the blocks. An auto-regressive type 1 covariance matrix was employed as determined using Akaike's information criteria. Abnormal fecal score days and medical days were summed over phase 1 and analyzed using Kruskal-Wallis test with Proc NPAR1WAY in SAS. Calf (1 calf per pen) was the experimental unit. In phase 2, intake and growth data were analyzed as a completely randomized block design with repeated measures when applicable (grouped by two 28-d periods for body measurements) by Proc Mixed in SAS. An auto-regressive type 1 covariance matrix was employed as determined using Akaike's information criteria. Pen was the experimental unit. Significance was determined at *P* ≤ 0.05. Trends were considered at *P* ≤ 0.09.

RESULTS AND DISCUSSION {#s0020}
======================

Initial measurements on d 0 of phase 1 did not differ ([Table 2](#t0015){ref-type="table"} ). No preweaning measurements differed. Postweaning starter intake (2.13 vs. 2.00 kg/d) and ADG (0.94 vs. 0.86 kg/d) were greater (*P* \< 0.01) for TUL than CON. Overall ADG (0.69 vs. 0.66 kg/d) and final BW (78.0 vs. 77.6 kg) were greater (*P* \< 0.05) for TUL than CON. Medical treatment d did not differ. For CON, there were 5 calves treated for navel infections and 2 calves treated for BRD (symptoms were nasal discharges with fever and lethargy). For TUL, there were 6 calves treated for navel infections and 1 calf treated for BRD (a symptom of nasal discharge). All navel infections were identified and treatments began on d 0. No abnormal breathing sounds were detected by auscultation on d 28, 42, or 56. Abnormal fecal score also did not differ. All fecal samples from calves with abnormal feces tested positive for *Cryptosporidium* and *Rotavirus.* During phase 2, DMI did not differ; however, DMI as a percentage of BW (2.97 vs. 2.81% of BW) was greater (*P* \< 0.01) for CON than TUL ([Table 3](#t0020){ref-type="table"} ). Calf ADG (1.21 vs. 1.08 kg/d), final BW (137.8 vs. 145.8 kg), feed efficiency (0.369 vs. 0.331 G:F), and hip width change (5.5 vs. 4.8 cm) were greater (*P* \< 0.03) for TUL than CON. Over the 112 d of both phases, the difference in BW was 9.0 kg (9%) of BW (106.4 kg for TUL and 97.4 kg for CON) and 0.8 cm (8%) for hip width change (10 cm for TUL and 9.2 cm for CON).Table 2Performance of calves (48 per treatment) from 0 to 56 d (phase 1) that had not been treated (CON) or were treated (TUL) with Draxxin[1](#tf0020){ref-type="table-fn"} (2.5 mg of tulathromycin/kg of BW) near birth and weaning (43 d apart)Table 2ItemCONTULSEM*P*-valueInitial serum protein, mg/dL5.55.60.140.08Initial BW, kg40.639.31.080.86Final BW, kg77.678.00.140.05Initial hip width, cm17.116.80.280.70Final hip width, cm21.621.40.200.31Initial BCS[2](#tf0025){ref-type="table-fn"}2.12.10.040.51Final BCS2.42.40.030.19Before weaning (0 to 42 d) Starter intake, kg/d0.440.490.0420.32 ADG, kg/d0.600.610.0230.38 Feed efficiency[3](#tf0030){ref-type="table-fn"}0.5410.5280.02010.98 Hip width change, cm2.83.10.210.26 BCS change0.20.20.040.79 Fecal score[4](#tf0035){ref-type="table-fn"}2.12.10.020.87 Abnormal fecal days,[5](#tf0040){ref-type="table-fn"} no.0.10.10.070.70 Medical days, no.0.80.90.230.20After weaning (43 to 56 d) Starter intake, kg/d2.002.130.0510.01 ADG, kg/d0.860.940.0140.01 Feed efficiency0.4350.4400.03550.42 Hip width change, cm1.71.50.160.78 BCS change0.10.10.030.76 Fecal score2.02.00.030.89 Abnormal fecal days, no.0.00.0------ Medical days, no.0.00.10.130.72Overall Starter intake, kg/d0.830.900.0390.08 ADG, kg/d0.660.690.0090.02 Feed efficiency0.5150.5060.01740.70 Hip width change, cm4.44.50.230.22 BCS change0.30.30.050.63 Fecal score2.02.00.010.94 Abnormal fecal days, no.0.10.050.080.11 Medical days, no.0.81.00.270.20[^3][^4][^5][^6][^7]Table 3Performance of calves (12 pens per treatment, 4 calves per pen) from 56 to 112 d (phase 2) that had not been treated (CON) or were treated (TUL) with Draxxin[1](#tf0045){ref-type="table-fn"} (2.5 mg of tulathromycin/kg of BW) near birth and weaning (43 d apart)Table 3ItemCONTULSEM*P*-valueInitial BW, kg77.678.01.740.26Final BW, kg137.8145.21.880.01Initial hip width, cm21.621.40.180.76Final hip width, cm26.327.10.220.03Initial BCS[2](#tf0050){ref-type="table-fn"}2.42.40.040.22Final BCS2.92.90.040.94DMI, kg/d3.33.30.050.49DMI, % of BW2.972.810.0260.01ADG, kg/d1.081.210.0130.01Feed efficiency,[3](#tf0055){ref-type="table-fn"} G:F0.3310.3690.00610.01Hip width change, cm4.85.50.150.01BCS change0.50.50.040.23[^8][^9][^10]

Stressors are a trigger of disease in calves through their effect on cortisol and various cytokines, and stressors occur frequently in the first 2 mo of life ([@bb0035]). Significant stressors in the life of a calf include castration, dehorning, weaning, commingling, and vaccination ([@bb0035]), and these stressors frequently occur after 3 wk of age when respiratory disease is most prevalent. Stressors combined with the presence of viruses allow bacterial colonization of the lungs and are a typical reason for the onset of respiratory disease ([@bb0100]). A common outcome of BRD in calves is decreased weight gain and wither height. Indeed, [@bb0050] showed that calves that developed BRD before 8 wk of age experienced decreased weight gain and wither height. Detection can be difficult but critical to treatment, and recovery from the disease can affect performance later in life. This was demonstrated in a study with 795 Holstein calves where identification and treatment of disease before 2 mo of age improved first- and subsequent-lactation milk production ([@bb0030]).

Calves in the current trial faced many stressors including a 3.5-h transport from their birth farm to the research facility, several vaccinations, castrating, dehorning, weaning, and commingling. Over the 112 d on trial, the calves appeared healthy based on the few illnesses identified. Navel infections on d 0 were the predominate illness identified. These infections were evenly distributed between CON and TUL calves. All but one calf with a navel infection did not have iodine-stained hair around their navels as calves did without navel infections; thus, source-farm personnel likely did not properly dip their navels at birth.

In the studies by [@bb0050], [@bb0055], [@bb0060]), calves previously treated for respiratory disease had decreased growth and increased mortality rates later in life than calves not treated for respiratory disease. [@bb0060] compared metaphylactic treatment with TUL at approximately 3 d of age with no treatment and reported that calves treated with TUL had a lower incidence of diarrhea, otitis media, and an approximately 4% increase in BW gain (0.02 kg/d) between 3 d and 2 mo of age.

[@bb0050], [@bb0055]) reported that ADG and height gain was not altered by TUL versus oxytetracycline treatment at approximately 2 mo of age in calves that had a respiratory disease before approximately 3.2 mo of age. However, in calves without disease, ADG (0.13 kg/d) and withers height gain (0.04 cm/d) were increased by TUL versus oxytetracycline metaphylactic treatment. Our improvement in both BW gain and hip width gain between TUL and CON was consistent with the report by [@bb0050], [@bb0055]).

[@bb0055] followed the same group of calves from their 2010 study to 13 mo of age and found that calves never treated for respiratory disease maintained heavier BW at 3, 6, 9, and 13 mo of age if treated metaphylactically with TUL versus oxytetracycline. However, the effect of TUL on withers height growth after approximately 3 mo of age was uncertain, but wither heights of all calves (healthy and sick) were greater at 9 mo with TUL versus oxytetracycline treatment.

[@bb0055], [@bb0060]) attributed improvements in growth to reduction of disease in calves. In our studies, the identification of disease was low. We speculate that that there was some level of BRD that was not identified and that TUL may have reduced subclinical disease to allow for more BW and structural growth.

In our trial, healthy calves gained approximately 8% more BW and hip width from 3 d to 4 mo of age. In the trials by [@bb0050], [@bb0055], [@bb0060]), healthy calves experienced improved BW and structural growth in the first 3 mo of age when metaphylactically administered TUL. Growth experienced in the first 3 mo of life appeared to be maintained to approximately 12 mo of age in the study by [@bb0055]. Because our calves appeared healthy and the medical treatments of CON were low, medical treatments for disease were not affected by TUL. Under the conditions of our study with healthy calves, TUL improved calf BW and hip width gain from 3 d to 4 mo of age by approximately 8%.

IMPLICATIONS {#s0025}
============

Metaphylactic treatment of dairy calves with Draxxin (2.5 mg of tulathromycin/kg of BW) near birth (approximately 3 d of age) and 43 d later at weaning increased BW and hip width gain by approximately 8% from 0 to 4 mo of age. In general, calves in the trial were healthy, and few calves were treated for respiratory and enteric disease.
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[^1]: Manufactured with whey, whey protein concentrate, and animal fat.

[^2]: Manufactured with 37% whole corn, 35% protein--mineral pellet, 25% whole oats, and 3% liquid molasses.

[^3]: Zoetis (Florham Park, NJ).

[^4]: A 1-to-5 point system with 1 being thin and 5 being obese, modified from [@bb0095].

[^5]: Feed efficiency was calculated as BW gain divided by the sum of milk replacer and starter intake.

[^6]: Feces were scored daily using a 1-to-5 scale with 1 being normal and 5 being watery, modified from [@bb0040].

[^7]: Days with fecal scores of 3 or greater.

[^8]: Zoetis (Florham Park, NJ).

[^9]: A 1-to-5 point system with 1 being thin and 5 being obese, modified from [@bb0095].

[^10]: Feed efficiency was calculated as BW gain divided by DMI.
